Lung Adenocarcinoma - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 57

Lung Adenocarcinoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Lung Adenocarcinoma - Pipeline Review, H2 2012', provides an overview of the Lung Adenocarcinoma therapeutic pipeline. This report provides information on the therapeutic development for Lung Adenocarcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma. 'Lung Adenocarcinoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Adenocarcinoma.
- A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lung Adenocarcinoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Lung Adenocarcinoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Lung Adenocarcinoma Therapeutic Products under Development, Key Players in Lung Adenocarcinoma Therapeutics, Lung Adenocarcinoma Pipeline Overview, Lung Adenocarcinoma Pipeline, Lung Adenocarcinoma Pipeline Assessment

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Lung Adenocarcinoma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Lung Adenocarcinoma 8
Lung Adenocarcinoma Therapeutics under Development by Companies 10
Lung Adenocarcinoma Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Lung Adenocarcinoma Therapeutics – Products under Development by Companies 17
Lung Adenocarcinoma Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Lung Adenocarcinoma Therapeutics Development 19
Boehringer Ingelheim GmbH 19
Amgen Inc. 20
Morphotek, Inc. 21
BioNumerik Pharmaceuticals, Inc. 22
Lung Adenocarcinoma – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
MT110 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Tavocept - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Tarceva - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Afatinib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Tavocept + Cisplatin + Docetaxel - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Sorafenib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Erlotinib + Docetaxel + Cisplatin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 40
Erlotinib + Pemetrexed + Cisplatin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MORAb-003 + Carboplatin + Paclitaxel - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
licofelone - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MORAb-003 + Carboplatin + Pemetrexed - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
MORAb-003 + Cisplatin + Pemetrexed - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Metformin + Paclitaxel + Carboplatin + Bevacizumab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 50
Lung Adenocarcinoma Therapeutics – Drug Profile Updates 50
Lung Adenocarcinoma Therapeutics - Dormant Products 54
Lung Adenocarcinoma – Product Development Milestones 55
Featured News & Press Releases 55
Apr 20, 2012: Endocyte Presents Data On Vintafolide At European Lung Cancer Conference 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57

List of Tables
Number of Products Under Development for Lung Adenocarcinoma, H2 2012 8
Products under Development for Lung Adenocarcinoma – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Boehringer Ingelheim GmbH, H2 2012 19
Amgen Inc., H2 2012 20
Morphotek, Inc., H2 2012 21
BioNumerik Pharmaceuticals, Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Lung Adenocarcinoma Therapeutics – Drug Profile Updates 50
Lung Adenocarcinoma Therapeutics – Dormant Products 54

List of Figures
Number of Products under Development for Lung Adenocarcinoma, H2 2012 8
Products under Development for Lung Adenocarcinoma – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28

Customers who bought this item also bought

• Lung Infections – Pipeline Review, H1 2013
• Non-Small-Cell Lung Cancer (Event Driven)
• Drug Addiction – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Oncology Intelligence: A Comprehensive Report for Decision Making